Last update 29 Jun 2024
Rituximab biosimilar(Genor Biopharma Co., Ltd.)
Last update 29 Jun 2024
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms Rituximab biosimilar, 重组抗CD20人鼠嵌合单抗 (嘉和生物), GB-241 + [1] |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Gene Sequence
Sequence Code 27145L
The sequence is quoted from: *****
Sequence Code 83181H
The sequence is quoted from: *****
Related
4
Clinical Trials associated with Rituximab biosimilar(Genor Biopharma Co., Ltd.)比较G-CHOP与R-CHOP在初治的CD20阳性DLBCL患者中的有效性和安全性的临床试验
[Translation] A clinical trial comparing the efficacy and safety of G-CHOP and R-CHOP in patients with previously untreated CD20-positive DLBCL
A Multi-center, Randomized, Double-blind, Controlled, and Parallel Phase III Study to Compare the Efficacy and Safety of GB241 (Recombinant Anti-CD20 Human-Mouse Chimeric Monoclonal Antibody Injection, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated Diffuse Large B-cell Lymphoma (DLBCL) Patients
比较重组抗CD20人鼠嵌合单克隆抗体注射液与利妥昔单抗在CD20阳性淋巴瘤患者中的PK、PD和安全性的临床研究
[Translation] A clinical study comparing the PK, PD and safety of recombinant anti-CD20 human-mouse chimeric monoclonal antibody injection and rituximab in patients with CD20-positive lymphoma
100 Clinical Results associated with Rituximab biosimilar(Genor Biopharma Co., Ltd.)
Login to view more data
100 Translational Medicine associated with Rituximab biosimilar(Genor Biopharma Co., Ltd.)
Login to view more data
100 Patents (Medical) associated with Rituximab biosimilar(Genor Biopharma Co., Ltd.)
Login to view more data
100 Deals associated with Rituximab biosimilar(Genor Biopharma Co., Ltd.)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | Phase 3 | CN | 28 Dec 2018 | |
| CD20 positive Non-Hodgkin Lymphoma | Phase 1 | CN | 05 Jun 2017 | |
| CD20 positive Non-Hodgkin Lymphoma | Phase 1 | CN | 05 Jun 2017 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free